What must CROs deliver Orphan Drug Developers?

In Clinical Development, Partnering & Investment by Matt Turner

orphan drugs, rare diseases, CRO, clinical trials, partnering, collaboration

Specialist trials for rare diseases provide unique challenges to the pharma industry, particularly when it comes to patient recruitment and retention. And with so many clinical trials being outsourced to external expertise, what are the top tips for orphan drug developers seeking a CRO & what do pharma and biotech look for in a rare disease CRO partner?

Download this eBook to:

  • Understand the orphan drug clinical trial landscape
  • Learn the concerns & challenges of pharma companies when it comes to orphan drug clinical development
  • Compare and contrast rare and common clinical trials
  • Discover how specialist-CROs are collaborating with pharma partners to create custom-made strategies
  • Read about what developers look for in a potential CRO partner

By definition, rare disease trials suffer from small numbers of available patients per country and to compound this issue, expert centres to run these trials are few and far between. The rarer the disease, the more significant these challenges become and the greater need for external expertise to overcome development hurdles.

Download the eBook to gain insight into how specialised CRO’s are providing that external expertise and undertaking clinical research for pharma and biotech companies

The World Orphan Drug Congress is the premier commercial marketplace where pioneering CROs and orphan drug developers will moderate discussion, interact and present on how to make orphan drug trials feasible, optimise clinical development and accelerate the market approval process. Leading industry executives debate and shape best practice to optimise orphan drug development and ensure sustainable production of rare disease treatments.